Clinical Trials Logo

Clinical Trial Summary

Background:

Age-related macular degeneration (AMD) is the leading cause of blindness in the United States. Currently, there is no safe way to obtain cells from the eye to study. But researchers now can turn other types of cells, like skin or blood, into induced pluripotent stem (iPS) cells. These can be grown in a lab and turned into other types of cells, like cells from the eye. This will allow researchers to understand and treat diseases of the eye such as AMD.

Objectives:

To establish a bank of samples that can be changed into other cell types, such as eye cells, to better understand diseases such as AMD. Also to test drugs in order to treat various eye diseases.

Eligibility:

People who provided DNA samples in another protocol (07-EI-0025)

Design:

Participants will be screened with their data from the previous protocol. Participants with select genetic variants will be chosen and contacted via phone.

Participants will have a punch skin biopsy. The skin will be washed. A numbing medication will be injected. A small piece of skin will be removed with a biopsy tool. The site will be covered with a dressing. They will receive instructions on how to care for the area. They will have follow-up visits if needed for clinical care for the area.

Participants may be asked to return if their first sample did not provide enough cells for the lab.

Participants sample will be developed into eye cells. The cells will be used to understand diseases and test new drugs.


Clinical Trial Description

Objective: This ancillary study will establish a repository of biospecimens to generate induced pluripotent stem (iPS) cells that can be differentiated into ocular cell types, to be used for study of molecular mechanisms of and development of treatments for age-related macular degeneration (AMD). This repository will allow the cells to be used to perform high throughput drug screens to identify novel potential therapeutic compounds. Although research involving multiple different ocular cell types from these patients may be performed, the vast majority of the work will be centered on the retinal pigment epithelium (RPE) and neural retina. RPE and/or neural retinal cells generated from the iPS cells of participants with AMD will be used to analyze molecular mechanisms involved in disease initiation and progression.

Study Population: We plan to recruit 100 participants across multiple sites with AMD from the original cohort of study participants enrolled in the AREDS2 who are returning for a 10 year in-clinic study visit and have donated DNA in the AREDS2 study. Up to two participants will be enrolled at NEI. Participants with the highest genetic burden as well as those with rare variants will be included in the population.

Design: A 520 blood sample will be collected from 350 participants with specific genetic variants that are identified prior to the start of the study. Up to 60 participants will be enrolled at NEI. All of these participants were previously enrolled in the AREDS2 protocol (07-EI-0025) and they are returning for a 10-year in-clinic study visit for further phenotyping and for assessing the long-term effects of the ARESD2 supplements. Collected samples will be used to analyze molecular mechanisms involved in disease initiation and progression. In addition, the iPS cell-derived ocular cells may be used to perform high throughput (HTP) drug screens aimed at suppressing the molecular phenotypes of the disease and to identify potential therapeutic agents for these diseases. This study will typically require only one visit by each participant.

Outcome Measures: The primary outcome is to develop a repository for iPS cells for investigators involved in vision research. Secondary outcomes include the assessment of potential therapies for the treatment of age related macular disorder (AMD). There are no specific participant-based clinical outcomes for this protocol. Participants will, in general, be seen only once for this protocol, as this is an ancillary study to the main study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03372746
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase
Start date May 23, 2018
Completion date March 21, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Recruiting NCT03893474 - Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners N/A
Completed NCT00971464 - Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation Phase 2
Terminated NCT00332657 - Anecortave Acetate Risk Reduction Trial (AART) Phase 3
Recruiting NCT04796545 - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration N/A
Completed NCT01766596 - Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort) N/A
Completed NCT03322930 - Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
Completed NCT01778491 - AMD Phenotype and Genotype Study
Completed NCT01016873 - INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD Phase 2
Active, not recruiting NCT03845582 - Phase 3 Study of ALK-001 in Geographic Atrophy Phase 3
Completed NCT03367767 - Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
Terminated NCT00333216 - Anecortave Acetate Risk-Reduction Trial (AART) Phase 3
Completed NCT01570790 - Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT00346866 - Anecortave Acetate Versus Placebo in AMD Patients Following PDT Phase 2
Withdrawn NCT00726466 - Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration Phase 1
Completed NCT00306488 - OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration Phase 2
Terminated NCT02348359 - X-82 to Treat Age-related Macular Degeneration Phase 2
Completed NCT01632527 - Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD) Phase 1/Phase 2
Withdrawn NCT01339949 - Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV) N/A
Recruiting NCT03675880 - TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects Phase 1